1. Home
  2. MREO

MREO

Mereo BioPharma Group plc

Logo Mereo BioPharma Group plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-17-2024 11:51am EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).

Founded: 2015 Country:
United Kingdom
United Kingdom
Employees: N/A City: LONDON
Market Cap: 444.6M IPO Year: N/A
Target Price: $6.50 AVG Volume (30 days): 1.7M
Analyst Decision: Strong Buy Number of Analysts: 2
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.25 EPS Growth: N/A
52 Week Low/High: $0.92 - $4.36 Next Earning Date: 03-27-2024
Revenue: $10,000,000 Revenue Growth: -78.06%
Revenue Growth (this year): 121.95% Revenue Growth (next year): -54.54%

Share on Social Networks: